Please login to the form below

Not currently logged in
Email:
Password:

Common ICU drug blocks cardiovascular effects of cocaine

An intensive care unit drug commonly used as a sedative may have the ability to counteract the effects of cocaine on the human cardiovascular system, according to a US study

An intensive care unit drug commonly used as a sedative may have the ability to counteract the effects of cocaine on the human cardiovascular system, according to a US study.

Doctors at UT Southwestern Medical Center published details of their discovery in the 14 August issue of the Journal of the American College of Cardiology.

Precedex (dexmedetomidine), which is manufactured by US-based Orion, was found to lower the heart rate and blood pressure in a clinical trial involving 22 volunteers who had taken a small dose of the drug. Researchers also found that the drug reduced sympathetic nerve activity in the subjects who had taken cocaine.

Dr Wanpen Vongpatanasin, the study's senior author, said: "We have found that cocaine's effects on the cardiovascular system can be reversed by dexmedetomidine, which is currently approved by the FDA for anaesthetic purposes in operating rooms or intensive care units."

The new treatment would prove superior to the current regimen of nitroglycerin, sedatives and blood pressure medications used to treat cocaine-induced medical disorders, because dexmedetomidine also reverses cocaine's adverse effects on heart rate, blood pressure and vascular resistance.

The study authors said further research was needed to see if dexmedetomidine could be used to treat acute cocaine overdose in accident and emergency units.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics